NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
Clinical safety rating: safe
Other nephrotoxic or ototoxic drugs increase risk of toxicity Can cause ototoxicity and nephrotoxicity with systemic use.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. Dexamethasone is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby suppressing prostaglandin and leukotriene synthesis, reducing inflammation.
| Metabolism | Neomycin is minimally absorbed and excreted unchanged in urine. Dexamethasone is hepatically metabolized via CYP3A4. |
| Excretion | Neomycin is primarily excreted unchanged in feces (~97%) after oral administration, with about 1% absorbed and renally excreted. Dexamethasone is metabolized in liver and excreted renally (~65% as metabolites, 2-5% unchanged) and in feces (~20%). |
| Half-life | Neomycin: terminal half-life ~2-3 hours after oral absorption (negligible systemic absorption); in renal impairment, half-life can extend to 12-24 hours. Dexamethasone: terminal half-life ~36-54 hours (mean ~48 hours) in adults. |
| Protein binding | Neomycin: negligible protein binding (<10%). Dexamethasone: ~77% bound primarily to albumin. |
| Volume of Distribution | Neomycin: Vd ~0.1-0.2 L/kg (confined to extracellular fluid due to hydrophilic nature). Dexamethasone: Vd ~0.5-0.8 L/kg, indicating wide distribution including intracellular and central nervous system. |
| Bioavailability | Neomycin: oral bioavailability <3% (nearly negligible systemic absorption). Dexamethasone sodium phosphate: oral bioavailability ~80-90% (as dexamethasone); IV and ophthalmic administration yield 100% systemic availability for the absorbed fraction, though ophthalmic dose is negligible systemically. For the combination product, systemic absorption from ophthalmic drops is minimal. |
| Onset of Action | Neomycin oral: onset within 1-2 hours for bowel sterilization; ophthalmic drops: rapid (minutes) for anti-infective effect. Dexamethasone sodium phosphate: IV onset immediate (minutes); ophthalmic drops: onset within 1-2 hours for anti-inflammatory effect. |
| Duration of Action | Neomycin oral: duration ~6-8 hours for bowel sterilization; ophthalmic: duration ~4-6 hours. Dexamethasone: IV duration ~12-36 hours for anti-inflammatory effect (dose-dependent); ophthalmic: duration ~6-8 hours. |
| Molecular Weight | Neomycin sulfate: 908.88 Da; Dexamethasone sodium phosphate: 516.41 Da |
Ophthalmic: 1-2 drops of the solution or small amount of the ointment (approximately 1/2 inch into the conjunctival sac) every 3-4 hours, or more frequently if needed. Otic: 4 drops into the affected ear 3-4 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific dose adjustment guidelines available for ophthalmic/otic use; systemic absorption is minimal, but caution in severe renal impairment if used on large denuded areas. |
| Liver impairment | No specific dose adjustment guidelines available for ophthalmic/otic use; systemic absorption is minimal, and hepatic impairment is unlikely to affect topical dosing. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established for ophthalmic or otic use; use only if clearly needed and with caution, dosing similar to adults but adjusted by severity and response. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to increased risk of adverse effects from systemic absorption if applied to large areas or broken skin. |
| 1st trimester | Neomycin sulfate: Not recommended due to potential ototoxicity and nephrotoxicity; avoid unless essential. Dexamethasone: Avoid as first-line; animal studies show increased risk of cleft palate; use only if maternal benefit outweighs risk. |
| 2nd trimester | Neomycin sulfate: Avoid due to minimal systemic absorption but potential fetal risk. Dexamethasone: Use if clearly needed; monitor for intrauterine growth restriction (IUGR) and adrenal suppression. |
| 3rd trimester | Neomycin sulfate: Avoid; may cause neonatal nephrotoxicity/ototoxicity. Dexamethasone: Use with caution near term; may cause neonatal hypothalamic-pituitary-adrenal (HPA) axis suppression. |
Clinical note
Other nephrotoxic or ototoxic drugs increase risk of toxicity Can cause ototoxicity and nephrotoxicity with systemic use.
| FDA category | Animal |
| Placental transfer | Neomycin sulfate: Negligible placental transfer after topical use; systemic absorption minimal. Dexamethasone: Crosses placenta efficiently (approximately 67% reaches fetal circulation); inactivated to some extent by placental 11β-HSD2. |
■ FDA Black Box Warning
Neomycin sulfate can cause nephrotoxicity and ototoxicity, even with ophthalmic use, especially in patients with renal impairment or prolonged use. Risk is dose- and duration-dependent.
| Common Effects | topical infections |
| Serious Effects |
Hypersensitivity to neomycin, dexamethasone, or any componentFungal, viral (herpes simplex, vaccinia, varicella), or mycobacterial ocular infectionsUntreated purulent ocular infectionsPerforated tympanic membrane (for otic use)Known or suspected myasthenia gravis (neomycin may exacerbate)
| Precautions | Prolonged use may lead to secondary infections (fungal, resistant bacteria)., Neomycin: nephrotoxicity, ototoxicity (including vestibular and cochlear damage), especially with accumulation in renal impairment., Dexamethasone: adrenal suppression, increased intraocular pressure, cataract formation, delayed wound healing., Hypersensitivity reactions to neomycin or cross-sensitivity to other aminoglycosides., Use with caution in patients with glaucoma, diabetes, or tuberculosis. |
Loading safety data…
| Breastfeeding | Topical neomycin sulfate is minimally absorbed systemically and unlikely to appear in breast milk. Dexamethasone is excreted in breast milk in small amounts; prolonged high-dose systemic use may suppress infant adrenal function. Use with caution; avoid application to breast area. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Pregnancy Category D. First trimester: Corticosteroid use associated with cleft palate (2-3 fold increased risk). Aminoglycosides may cause fetal ototoxicity but risk is low with topical/ophthalmic use. Second and third trimesters: Potential for fetal adrenal suppression with prolonged maternal corticosteroid use. Avoid systemic use if possible. |
| Fetal Monitoring | Monitor maternal blood glucose (corticosteroid-induced hyperglycemia). Assess fetal growth and amniotic fluid index with prolonged use. In cases of systemic absorption (e.g., extensive skin breakdown), monitor audiometry and renal function for aminoglycoside toxicity. |
| Fertility Effects | No known direct effect on fertility. High-dose corticosteroids may disrupt menstrual cycles, potentially affecting ovulation. Aminoglycosides not associated with fertility impairment. |
| Food/Dietary | No significant food interactions for ophthalmic use. However, excessive sodium intake should be avoided in patients with hypertension, though systemic absorption from eye drops is minimal. |
| Clinical Pearls | This ophthalmic combination is used for steroid-responsive inflammatory ocular conditions where bacterial infection or risk of infection exists. Dexamethasone is a potent corticosteroid; prolonged use may increase intraocular pressure (IOP) in susceptible patients. Monitor IOP if used for >10 days. Neomycin is an aminoglycoside antibiotic; topical use carries risk of sensitization and allergic contact dermatitis. Do not use in patients with epithelial herpes simplex keratitis, mycobacterial infections, or fungal diseases. Shake well before instillation. Do not touch dropper tip to any surface. |
| Patient Advice | Shake the bottle well before each use. · Avoid touching the dropper tip to your eye or any surface. · Wait at least 5 minutes between different eye drops if using more than one. · Do not wear contact lenses during treatment unless directed by your doctor. · Report any eye pain, vision changes, or worsening redness immediately. · Complete the full course of treatment even if symptoms improve. |